Retatrutide 10mg Includes 2mL Bacteriostatic Water

Retatrutide (Triple GLP-1/GIP/Glucagon Agonist) – 10 mg Dosage Protocol

Retatrutide is an investigational peptide that acts as a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, supporting appetite suppression, fat metabolism, and improved energy expenditure. By combining these pathways, it offers a comprehensive approach to weight management and metabolic optimization.

Clinical research has demonstrated significant weight loss and metabolic improvements, with gradual dose escalation improving tolerability and minimizing gastrointestinal side effects.

This educational protocol outlines a once-weekly subcutaneous dosing strategy using a practical dilution for precise measurement.

---

Reconstitute:
Add 2.0 mL bacteriostatic water → ~5 mg/mL (5000 mcg/mL) concentration (based on a 10 mg vial)

---

Typical Weekly Protocol (Titration):

• Week 1–4: 0.5 mg once weekly
• Week 5–8: 1 mg once weekly
• Week 9–12: 2 mg once weekly
• Week 13+: 3–4 mg once weekly (as tolerated)

---

Easy Measuring:
At 5 mg/mL,

• 1 unit = 0.01 mL ≈ 50 mcg on a U-100 insulin syringe

Example:

• 0.5 mg dose ≈ 10 units
• 1 mg dose ≈ 20 units
• 2 mg dose ≈ 40 units
• 4 mg dose ≈ 80 units

---

Administration:

• Subcutaneous injection (abdomen, thigh, or upper arm)
• Once weekly, same day each week
• Rotate injection sites

---

Storage:

• Lyophilized: Store at −20 °C (−4 °F)
• After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F)
• Protect from light and avoid repeated freeze–thaw cycles

---

Note:
Retatrutide is currently under investigation for obesity and metabolic disorders, showing promising results in fat loss, appetite control, and insulin sensitivity improvement. Common side effects may include nausea, reduced appetite, or mild fatigue, particularly during dose escalation.